About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Kinematic Assessment In Multiple Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04283071

Kinematic Assessment In Multiple Sclerosis

Multiple sclerosis (MS) affects more than a 120,000 people in the United Kingdom and is the commonest neurological condition in young adults. MS causes a number of symptoms including weakness, altered...

Lead sponsor: The Leeds Teaching Hospitals NHS Trust•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The Leeds Teaching Hospitals NHS Trust

Collaborators

University of Leeds

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age above 18 years at the time of enrolment into the study
•Participants with a confirmed diagnosis of MS that have entered the primary or secondary progressive stage for at least 12 months
•Participants must be able to comply with the terms and methods of the protocol
•Study specific written informed consent has been obtained

Exclusion Criteria

•Age below 18 years at the time of enrolment into the study
•Participants with a diagnosis of RRMS
•Participants unable to comply with the terms or methods of the protocol
•Participants who report any cognitive or memory impairment
•Participants with significant co-morbidities that affect their upper limb function i.e. stroke etc.

Related studies

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 · Multiple Sclerosis Spasticity

RECRUITINGPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 · Secondary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 7, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment57

Start dateNov 2019

Last updatedMar 7, 2022

Condition

Multiple Sclerosis

Locations shown

Leeds Teaching Hospitals NHS Trust

Leeds

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions